Quantinno Capital Management LP Boosts Stock Holdings in Xenon Pharmaceuticals Inc. $XENE

Quantinno Capital Management LP raised its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 125.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 55,444 shares of the biopharmaceutical company’s stock after acquiring an additional 30,816 shares during the period. Quantinno Capital Management LP’s holdings in Xenon Pharmaceuticals were worth $3,224,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in XENE. Cinctive Capital Management LP grew its position in shares of Xenon Pharmaceuticals by 1.1% during the fourth quarter. Cinctive Capital Management LP now owns 23,317 shares of the biopharmaceutical company’s stock valued at $1,045,000 after purchasing an additional 263 shares in the last quarter. State of Wyoming boosted its stake in Xenon Pharmaceuticals by 30.4% during the fourth quarter. State of Wyoming now owns 1,501 shares of the biopharmaceutical company’s stock valued at $67,000 after buying an additional 350 shares during the last quarter. Quarry LP boosted its stake in Xenon Pharmaceuticals by 25.0% during the third quarter. Quarry LP now owns 2,500 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 500 shares during the last quarter. Altfest L J & Co. Inc. grew its holdings in Xenon Pharmaceuticals by 6.5% during the 4th quarter. Altfest L J & Co. Inc. now owns 8,232 shares of the biopharmaceutical company’s stock valued at $369,000 after buying an additional 501 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its holdings in Xenon Pharmaceuticals by 11.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 6,574 shares of the biopharmaceutical company’s stock valued at $295,000 after buying an additional 675 shares in the last quarter. Institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Price Performance

Shares of XENE stock opened at $63.36 on Friday. The company has a market cap of $6.13 billion, a PE ratio of -13.37 and a beta of 0.62. Xenon Pharmaceuticals Inc. has a 1 year low of $32.78 and a 1 year high of $72.66. The stock’s 50 day simple moving average is $60.24 and its two-hundred day simple moving average is $54.20.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) EPS for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.05. During the same period in the previous year, the firm posted ($1.07) earnings per share. Equities research analysts expect that Xenon Pharmaceuticals Inc. will post -4.92 EPS for the current year.

Insiders Place Their Bets

In other Xenon Pharmaceuticals news, Director Gary Patou sold 1,322 shares of the business’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $70,251.08. Following the transaction, the director owned 24,896 shares in the company, valued at $1,322,973.44. The trade was a 5.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Gillian Cannon sold 1,190 shares of the stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $63,236.60. Following the completion of the sale, the director directly owned 1,455 shares in the company, valued at approximately $77,318.70. This represents a 44.99% decrease in their position. The SEC filing for this sale provides additional information. 2.91% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

XENE has been the topic of several recent research reports. Wells Fargo & Company reaffirmed an “overweight” rating and set a $69.00 price objective on shares of Xenon Pharmaceuticals in a report on Sunday, May 10th. Royal Bank Of Canada cut their target price on shares of Xenon Pharmaceuticals from $82.00 to $81.00 and set an “outperform” rating for the company in a report on Friday. Wall Street Zen raised shares of Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. Needham & Company LLC lowered their price objective on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating for the company in a research report on Friday, May 8th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 27th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $77.13.

Key Xenon Pharmaceuticals News

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Azetukalner NDA filing remains on track: Following an FDA meeting, RBC said Xenon still expects to submit a New Drug Application for azetukalner later this quarter. The filing is a major near-term catalyst for the company’s lead product candidate. Xenon Pharmaceuticals’ Azetukalner NDA Filing Remains on Track After FDA Meeting, RBC Says
• Positive Sentiment: Quarterly loss beat expectations: Xenon reported a second-quarter adjusted loss of $1.11 per share, narrower than analysts’ expected $1.16 loss. Management also said its cash position should fund operations into 2029, reducing immediate financing and dilution concerns. XENE’s Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus
• Neutral Sentiment: Pipeline remains the investment focus: Xenon has no reported product sales, so valuation depends largely on azetukalner’s clinical and regulatory progress. The company’s earnings call emphasized development plans and the anticipated NDA submission rather than near-term commercial revenue. Xenon Pharmaceuticals Q2 2026 Earnings Call Transcript
• Negative Sentiment: Losses continue to widen year over year: Although the quarterly loss beat estimates, the reported per-share loss was worse than the $1.07 loss recorded in the same period last year. With sales still nil and the company continuing to fund research and development, investors remain sensitive to execution and regulatory risks. Xenon Pharmaceuticals Q2 Loss Widens

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.